<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334125</url>
  </required_header>
  <id_info>
    <org_study_id>13938</org_study_id>
    <nct_id>NCT01334125</nct_id>
  </id_info>
  <brief_title>Adjunctive Metformin Therapy in Double Diabetes</brief_title>
  <acronym>AMTIDD</acronym>
  <official_title>Glycemic Control in Children and Adolescents With Double Diabetes: Trial of Optimized Insulin-Metformin Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The significance of this project is to investigate the effects of adjunctive metformin
      therapy in children and adolescents with double diabetes. Double diabetes describes a
      clinical state where an individual possesses features of both type 1 and type 2 diabetes.
      There is a paucity of data on the role of adjunctive metformin therapy in children and
      adolescents with double diabetes. To help fill this knowledge gap, the investigators propose
      a randomized, double-blind, placebo-controlled trial of metformin in double diabetes.
      Specifically, the investigators will evaluate changes in hemoglobin A1c and anthropometry in
      patients with a diagnosis of type 1 diabetes who also have features of type 2 diabetes or
      metabolic syndrome as well as patients with type 2 diabetes who possess diabetes-associated
      autoantibodies. This will help determine the safety profile, and efficacy of adjunctive
      metformin therapy in these subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this 12-month clinical trial, a 3-month run-in period will precede the interventional
      phase of the study. All patients will be placed on treat-to-target insulin regimen alone
      during the run-in phase. At the end of the 3-month run-in period, all participants will
      continue on treat-to-target insulin regimen, and will then be randomized to either of the 2
      arms of the study: an experimental arm, consisting of treat-to-target insulin regimen plus
      metformin, and a control arm consisting of treat-to-target insulin regimen plus placebo. Both
      the physicians and patients will be blinded to the oral agents being administered to
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Adjusted Hemoglobin A1c Over Time</measure>
    <time_frame>Baseline, 3mo, 6mo, and 9 months</time_frame>
    <description>Comparison of the baseline-adjusted differences in HbA1c between the metformin and placebo groups during the trial. Hemoglobin A1c is a marker of glycemic control. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Adjusted Changes in Lipid Profile Over Time</measure>
    <time_frame>Baseline, 3mo, 6mo, and 9 months</time_frame>
    <description>Comparison of the baseline-adjusted differences in total cholesterol/high density cholesterol index over time between the metformin and the placebo groups. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Adjusted Changes in Adiponectin/Leptin Ratio Over Time</measure>
    <time_frame>Baseline, 3mo, 6 mo, and 9 months</time_frame>
    <description>Comparison of the baseline-adjusted differences in adiponectin/leptin ratio over time between the metformin and the placebo groups. The reported values represented mean adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Minor, Major, and Nocturnal Hypoglycemia</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of the occurrence of hypoglycemic event requiring a third party assistance (major hypoglycemia) per subject during the study, and minor hypoglycemia (plasma glucose of &lt;60 mg/dL or no measurement), as well as nocturnal hypoglycemia (plasma glucose of ≤60 mg/dL between 11PM and 6AM).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 1000 mg once daily by mouth for 9 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules once daily by mouth for 9 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1000 mg once daily by mouth for 9 months</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules once daily by mouth for 9 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A. General inclusion criteria

          1. Ten to 20 years of age.

          2. Pubertal (Tanner stages 2-5, by examination).

          3. Hemoglobin A1c level of &gt; 8.0% in the 6 months prior to enrollment.

          4. All subjects must have access to a computer.

        B. Specific inclusion criteria: [Subjects could have either #1, or #2].

          1. Subjects with clinical and biochemical features of T2DM of &gt; 6mo duration who also
             have positive T1DM antibodies

               -  Clinical features: acanthosis nigricans, BMI &gt;85%

               -  Biochemical: evidence of insulin resistance at diagnosis

               -  fasting insulin &gt;27 uIU/mL(normal range 6-27) at a fasting blood glucose of ≥ 126
                  mg/dL, or

               -  fasting c-peptide level of &gt; 7.1 ng/mL (normal range 0.9 - 7.1), or

               -  Homeostasis model of insulin resistance of &gt;3.16

          2. Patients with T1DM of &gt; one yr duration with BMI &gt;85%

               -  Presentation with ketoacidosis at diagnosis

               -  C-peptide &lt;0.9 ng/mL (normal range 0.9 - 7.1),or (insulin &lt; 6 uIU/mL) (NR 6-27)
                  at diagnosis (when blood glucose is ≥ 126 mg/dL)

               -  Can be antibody positive or negative

               -  Increased insulin requirement (&gt;2 Units/kg/day)

        Exclusion Criteria:

          1. Subjects on weight altering medications, such as orlistat.

          2. Subjects with eating disorder

          3. Subjects on medications other than insulin and or metformin that may affect blood
             glucose level.

          4. Subjects with abnormal hepatic function tests.

          5. Subjects with nephropathy, defined in this case as an overnight albumin excretion rate
             of &gt;200 mcg/min using a first morning urine sample collection.

          6. Subjects with recurrent diabetes ketoacidosis (more than 2 episodes in the past 12
             months), or recurrent severe hypoglycemia (more than 2 episodes of hypoglycemia with
             altered level of consciousness, requiring assistance to treat in the past year).

          7. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate
             contraceptive measures.

          8. Known or suspected allergy to metformin.

          9. The receipt of any investigational drug within 6 months prior to this trial.

         10. Active malignant neoplasms.

         11. No access to a computer.

         12. Subjects currently taking metformin for clinical purposes are not eligible to be
             enrolled in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin U Nwosu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UmassMemorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Nwosu BU, Maranda L, Cullen K, Greenman L, Fleshman J, McShea N, Barton BA, Lee MM. A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes. PLoS One. 2015 Sep 14;10(9):e0137525. doi: 10.1371/journal.pone.0137525. eCollection 2015.</citation>
    <PMID>26367281</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2011</study_first_posted>
  <results_first_submitted>January 27, 2016</results_first_submitted>
  <results_first_submitted_qc>March 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2016</results_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Benjamin U. Nwosu</investigator_full_name>
    <investigator_title>Study Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Double Diabetes</keyword>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Obesity</keyword>
  <keyword>Acanthosis nigricans</keyword>
  <keyword>Diabetes associated autoantibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at a tertiary institution. The first patient was recruited on March 3rd 2011, and the last study patient was recruited on August 1, 2013. The study was closed on August 8, 2013.</recruitment_details>
      <pre_assignment_details>Following enrollment, all subjects entered a run-in phase of 3-month duration during which participants were placed on insulin aspart and insulin detemir, and the treat-to-target insulin regimen (TTIR) started.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>Metformin 1000 mg once daily by mouth for 9 months
Metformin: Metformin 1000 mg once daily by mouth for 9 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>1 capsule once daily by mouth for 9 months
Placebo: 1 capsule once daily by mouth for 9 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12">3 subjects move to another city</participants>
                <participants group_id="P2" count="10">3 subjects left for college and moved out of the area</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who completed the baseline evaluation at the time of randomization were included in the baseline analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>Metformin 1000 mg once daily by mouth for 9 months
Metformin: Metformin 1000 mg once daily by mouth for 9 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>1 capsule once daily by mouth for 9 months
Placebo: 1 capsules once daily by mouth for 9 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" spread="2.5"/>
                    <measurement group_id="B2" value="14.5" spread="3.1"/>
                    <measurement group_id="B3" value="14.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Adjusted Hemoglobin A1c Over Time</title>
        <description>Comparison of the baseline-adjusted differences in HbA1c between the metformin and placebo groups during the trial. Hemoglobin A1c is a marker of glycemic control. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).</description>
        <time_frame>Baseline, 3mo, 6mo, and 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin 1000 mg once daily by mouth for 9 months
Metformin: Metformin 1000 mg once daily by mouth for 9 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 capsule once daily by mouth for 9 months
Placebo: 1 capsules once daily by mouth for 9 months</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Adjusted Hemoglobin A1c Over Time</title>
          <description>Comparison of the baseline-adjusted differences in HbA1c between the metformin and placebo groups during the trial. Hemoglobin A1c is a marker of glycemic control. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).</description>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.46" lower_limit="8.47" upper_limit="10.46"/>
                    <measurement group_id="O2" value="9.85" lower_limit="8.82" upper_limit="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses were based on the intent-to-treat principle and were performed using SPSS v.22 (IBM Corporation, Armonk, NY).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.903</p_value>
            <p_value_desc>Individual two-way mixed ANOVA models were fitted for each of our outcomes of interest, with treatment type (metformin or placebo) as the fixed effect, and baseline values, age, gender, and BMI as covariates.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Adjusted Changes in Lipid Profile Over Time</title>
        <description>Comparison of the baseline-adjusted differences in total cholesterol/high density cholesterol index over time between the metformin and the placebo groups. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).</description>
        <time_frame>Baseline, 3mo, 6mo, and 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin 1000 mg once daily by mouth for 9 months
Metformin: Metformin 1000 mg once daily by mouth for 9 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 capsule once daily by mouth for 9 months
Placebo: 1 capsule once daily by mouth for 9 months</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Adjusted Changes in Lipid Profile Over Time</title>
          <description>Comparison of the baseline-adjusted differences in total cholesterol/high density cholesterol index over time between the metformin and the placebo groups. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="3.0" upper_limit="4.1"/>
                    <measurement group_id="O2" value="4" lower_limit="3.3" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses were based on the intent-to-treat principle and were performed using SPSS v.22 (IBM Corporation, Armonk, NY).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.578</p_value>
            <p_value_desc>Individual two-way mixed ANOVA models were fitted for each of our outcomes of interest, with treatment type (metformin or placebo) as the fixed effect, and baseline values, age, gender, and BMI as covariates.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Adjusted Changes in Adiponectin/Leptin Ratio Over Time</title>
        <description>Comparison of the baseline-adjusted differences in adiponectin/leptin ratio over time between the metformin and the placebo groups. The reported values represented mean adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).</description>
        <time_frame>Baseline, 3mo, 6 mo, and 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin 1000 mg once daily by mouth for 9 months
Metformin: Metformin 1000 mg once daily by mouth for 9 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 capsule once daily by mouth for 9 months
Placebo: 1 capsule once daily by mouth for 9 months</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Adjusted Changes in Adiponectin/Leptin Ratio Over Time</title>
          <description>Comparison of the baseline-adjusted differences in adiponectin/leptin ratio over time between the metformin and the placebo groups. The reported values represented mean adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.84" upper_limit="3.2"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.11" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Two way ANOVA comparison of the means of the adiponectin/leptin ratios between the metformin and placebo groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Minor, Major, and Nocturnal Hypoglycemia</title>
        <description>Comparison of the occurrence of hypoglycemic event requiring a third party assistance (major hypoglycemia) per subject during the study, and minor hypoglycemia (plasma glucose of &lt;60 mg/dL or no measurement), as well as nocturnal hypoglycemia (plasma glucose of ≤60 mg/dL between 11PM and 6AM).</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin 1000 mg once daily by mouth for 9 months
Metformin: Metformin 1000 mg once daily by mouth for 9 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 capsule once daily by mouth for 9 months
Placebo: 1 capsule once daily by mouth for 9 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Minor, Major, and Nocturnal Hypoglycemia</title>
          <description>Comparison of the occurrence of hypoglycemic event requiring a third party assistance (major hypoglycemia) per subject during the study, and minor hypoglycemia (plasma glucose of &lt;60 mg/dL or no measurement), as well as nocturnal hypoglycemia (plasma glucose of ≤60 mg/dL between 11PM and 6AM).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>p value represents the analysis for minor hypoglycemia</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>p value represents the analysis of the nocturnal hypoglycemia</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>Metformin 1000 mg once daily by mouth for 9 months
Metformin: Metformin 1000 mg once daily by mouth for 9 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>1 capsule once daily by mouth for 9 months
Placebo: 1 capsule once daily by mouth for 9 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Severe hypoglycemia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was stopped before reaching enrollment target because most youth were reluctant to commit to this long-term study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Benjamin U. Nwosu, MD</name_or_title>
      <organization>University of Massachusetts Medical School</organization>
      <phone>5083347872</phone>
      <email>Benjamin.Nwosu@umassmemorial.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

